☰

GuardTherapeutics

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of GuardTherapeutics's published strategy and is not endorsed by, or produced in cooperation with, GuardTherapeutics. Company website

Strategic priorities

GuardTherapeutics operates across 4 stated priorities, with the most concrete near-term plan anchored on value maximization through m&a.

Actively evaluating merger or reverse takeover options with Redeye AB as financial advisor, use the Nasdaq First North listing and remaining cash position as strategic assets.

Pivoting R&D focus to chemically synthesized peptides targeting chronic and rare kidney diseases including FSGS and Alport syndrome, with smaller molecular size enabling simplified manufacturing.

Conducting comprehensive analysis of AKITA and POINTER study data to identify patient sub-populations that showed positive response to A1M-based therapy.

Challenges we see

  • Operations Manufacturing

    Manufacturing model Transition

    The shift from recombinant biological production (RMC-035 in bacteria) to chemical peptide synthesis (GTX platform) requires fundamentally different data acquisition tools, quality standards, and manufacturing partnerships.

    The CMC team must manage this complex transition with reduced staff due to cost-cutting, increasing risks of manual errors and process inconsistencies during the critical pivot phase.

  • Digital Integration

    Decentralized Clinical Trial Data

    The POINTER study involved 170 patients across multiple international sites (Duke University, University of Virginia, Germany, Canada), with clinical data housed at various locations and analyzed locally.

    Digital fragmentation blocks the integrated multimodal data mining needed to identify high-responder sub-populations that could salvage the A1M platform for the GTX program.

  • Digital Operations

    Laboratory Digitalization Gap

    The Lund QC and bioanalysis hub relies on manual data entry and Excel-based tracking for critical regulatory submissions, creating a trust deficit between scientists and their data.

    Manual verification of complex analytical fields becomes a bottleneck for regulatory submissions and creates audit risk during M&A due diligence.

  • Operations Manufacturing

    CMO Information Latency

    As a virtual company entirely dependent on external CMOs, Guard only receives manufacturing data after batch completion or milestone achievement, lacking real-time process visibility.

    Inability to perform proactive process optimization or detect quality deviations in real-time drives risks of batch failures and regulatory compliance gaps.

  • Compliance Regulatory

    M&A Digital Readiness

    The strategic review requires presenting an impeccable audit-ready digital footprint to potential merger partners, with data integrity and cybersecurity as critical evaluation criteria.

    Current manual and siloed data infrastructure creates significant hurdles for digital due diligence, potentially reducing company valuation and limiting acquisition interest.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Clinical Data Integration Deficit

    Critical clinical trial data from AKITA and POINTER studies is fragmented across multiple international sites, preventing the integrated analysis needed to understand why RMC-035 failed and identify potentially responsive patient populations.

    Building a unified Industrial Data Platform that consolidates clinical data from all study sites would enable automated KPI engineering and post-hoc analysis to identify "Golden Batches" of responders, providing actionable intelligence to derisk the GTX platform.

  2. Paper-Based Laboratory Operations

    The Lund laboratory relies on manual data entry and Excel spreadsheets for bioanalysis and QC, creating data silos, transcription errors, and regulatory compliance risks that slow down submissions.

    Implementing a Digital Lab ecosystem with automated data capture from analytical instruments would eliminate manual errors, ensure GAMP5 compliance, and create an audit-ready infrastructure that enhances M&A attractiveness.

  3. Manufacturing Visibility Gap

    Guard's virtual model provides no real-time visibility into external CMO operations for the GTX peptide synthesis, with data only available post-batch completion, preventing proactive quality control.

    Deploying IT/OT convergence solutions with OPC UA protocols would create a "Single Source of Truth" dashboard showing real-time yield, batch consistency, and purity data from CMO partners.

  4. Digital Due Diligence Readiness

    The current manual and siloed data infrastructure cannot meet the digital maturity expectations of potential acquirers like large pharma companies with sophisticated ESG and compliance requirements.

    Implementing a Digital Maturity Roadmap with Zero Trust cybersecurity and automated ESG reporting would position Guard as a "digital-ready" acquisition target, maximizing valuation during the strategic review.

  5. Legacy System Interoperability

    The company's IT infrastructure consists of standalone workstations and heterogeneous devices from multiple vendors lacking unified communication protocols, creating broken data chains from sensor to dashboard.

    Implementing vendor-agnostic integration with standardized protocols (OPC UA, MTP) would enable "Plug & Produce" modularity, allowing rapid scaling of peptide production without vendor lock-in.

What we'd propose

  • Enterprise AI

    Integrated Clinical Data Platform

    A unified data platform that consolidates clinical trial data from multiple international sites, enabling automated KPI engineering and advanced analytics to identify patient response patterns and derisk future development.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Digital Lab Transformation for Lund QC Hub

    A comprehensive digitalization program for the Lund laboratory operations, replacing manual processes and Excel spreadsheets with automated data capture and GAMP5-compliant workflows.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    CMO Connectivity & Real-Time Manufacturing Intelligence

    An IT/OT convergence solution providing real-time visibility into external CMO operations for the GTX peptide synthesis program, enabling proactive quality management.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    M&A Digital Readiness Package

    A comprehensive digital infrastructure modernization program designed to maximize company valuation during the strategic review by demonstrating digital maturity to potential acquirers.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Modular Manufacturing Architecture for GTX Platform

    A vendor-agnostic system integration framework based on MTP standards enabling rapid scaling and flexible manufacturing partner selection for the GTX peptide platform.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what GuardTherapeutics's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration 25 → 80
Clinical trial data fragmented across international sites; lab data in Excel silos; no unified platform for analytics
Process Automation 30 → 75
Manual data entry in Lund lab; no real-time CMO visibility; limited automated quality control workflows
IT/OT Convergence 20 → 70
Standalone workstations with heterogeneous protocols; no OPC UA implementation; disconnected manufacturing systems
Cybersecurity 35 → 85
Basic perimeter security; no Zero Trust model; IP protection gaps for M&A data sharing
Regulatory Compliance 45 → 90
GAMP5 awareness but manual execution; paper-based audit trails; limited automated compliance monitoring
Analytics & AI 20 → 70
Post-hoc Excel analysis only; no predictive modeling; limited ML-based insights from clinical data

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with GuardTherapeutics, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].